Skip to content

Colorectal Cancer Health Center

Font Size

Gene Testing Predicts Response to Erbitux

Testing for KRAS Gene Pinpoints Which Patients Will Benefit From Targeted Therapy

'An Exciting Era'

Julie Gralow, MD, chairwoman of ASCO's communications committee and a cancer specialist at the University of Washington, says, "This is an exciting area of targeted agents."

Noting that therapies like Erbitux typically cost upwards of $5,000, Gralow says, "A big question is, how are we going to be able to afford these drugs in our patients? With KRAS testing, we can predict the two-thirds of patients who will benefit. We don't need to give this drug to the other third now."

That, she says, will spare them both the cost and side effects of unnecessary treatment. Gralow moderated a news conference to discuss the findings.


Today on WebMD

Colorectal cancer cells
The right diagnosis is the most important factor.
man with a doctor
Our health check will steer you in the right direction.
sauteed cherry tomatoes
Fight cancer one plate at a time.
bladder cancer x-ray
Do you know the warning signs?
Colon vs Rectal Cancer
New Colorectal Treatments
can lack of sleep affect your immune system
Cancer Facts Quiz
Virtual Colonoscopy
Picture of the Colon
Vitamin D

WebMD Special Sections